E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) |
pulmonal-arterielle Hypertonie (PAH) chronisch-thromboembolische
pulmonale Hypertonie (CTEPH) |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with pulmonary Hypertension |
Patienten mit Lungenhochdruck |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the benefits for PH patients from a long-term oxygen therapy (LTOT) given continuously during ≥16h/day for 12 weeks, measured by improvement of exercise performance assessed by the 6 minute walking distance (6MWD) |
|
E.2.2 | Secondary objectives of the trial |
1) To investigate effects of oxygen treatment on QoL, measured with SF-36 questionnaire 2) To determine the hemodynamic and functional responses during long term oxygen treatment by echocardiography and right heart catheterisation 3) To investigate the change of clinical parameters such as blood gas analysis, laboratory (NT-proBNP), WHO functional class (WHO-FC) 4) To assess time to worsening of oxygen saturation |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients in both groups (n = 40) with precapillary PH, WHO class I -IV (mPAP ≥ 25 mm Hg, pulmonary arterial occlusion pressure ≤15 mm Hg), who are stable on optimized pharmacological treatment for at least six weeks and who do not suffer from other cardio-pulmonary disease will be recruited if arterial or capillary O2 partial pressure is repeatedly (<60 mmHg; alternatively, 90% of O2 saturation) at rest and during physical activity hypoxemia still persist (O2 partial pressure <60 mmHg SpO2 90 % ). - men and women 18 years of age or older - patient is diagnosed with Pulmonary Arterial Hypertension (World Health Organization (WHO) Category Group 1-3 (by the WHO Clinical classification system)), including Idiopathic (IPAH), Heritable PAH (HPAH, Familial PAH), and CTEPH, with exceptions as noted in exclusion criteria - patient (or patient's legally authorized representative) is willing and able to provide written informed consent - patient is willing and able to comply with the protocol, including required follow-up visits - Patient experiences oxygen desaturations below 90% (or pO2 below 60 mmHg) at rest with oxygen desaturations below 90% (or pO2 below 60 mmHg) during physical activity - patient has a stable functional class of PAH with no changes of medication during the last six weeks before inclusion |
|
E.4 | Principal exclusion criteria |
- Patient is a female who is pregnant, nursing, or of child bearing potential and is not on a reliable form of birth control - patient has already been treated with long-term oxygen therapy within the last 3 weeks. - patient with pulmonary venous hypertension - significant functional limitation in lung function tests (FEV1>60%,TLC <60%) and CT morphological signs of pulmonary disease - significant left heart disease, requires acute pharmacological or interventional treatment - unstable conditions requiring pharmacological or other treatment, intensive care or relevant severe concomitant disease - patient is enrolled, has participated within the last thirty days, or is planning to participate, in a concurrent drug and/or device study during the course of this clinical trial. Co-enrolment in concurrent trials is only allowed with documented pre-approval from the study manager that there is not a concern that co-enrolment could confound the results of this trial. - patient has been initiated on a new oral or parenteral PAH therapy in the last two months - patient has had a recent (within three months) or otherwise unresolved infection requiring antibiotic treatment - patient with a cardiac index (CI) <1.8L/min/m2 - patient is Functional Class IV (New York Heart Association (NYHA)) active smoking status - patient with severe resting desaturation (repeatedly SpO2 ≤85%) or severe exercise-induced desaturation (SpO2 <80% for ≥10 minutes) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To determine the benefits for PH patients from a long-term oxygen therapy (LTOT) given continuously during ≥16h/day for 12 weeks, measured by improvement of exercise performance assessed by the 6 minute walking distance (6MWD) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 weeks after treatment start with or without oxygen |
|
E.5.2 | Secondary end point(s) |
- To investigate effects of oxygen treatment on QoL, measured with SF-36 questionnaire - To determine the hemodynamic and functional responses during long term oxygen treatment by echocardiography and right heart catheterisation - To investigate the change of clinical parameters such as blood gas analysis, laboratory (NT-proBNP), WHO functional class (WHO-FC) - To assess time to worsening of oxygen saturation and time to clinical worsening |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 weeks after treatment start with or without oxygen |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |